FVX

Fluvoxamine

Created: 2012-04-23
Last modified:  2021-03-01

Find related ligands:

Chemical Details

Formal Charge0
Atom Count43
Chiral Atom Count0
Bond Count43
Aromatic Bond Count6
2D diagram of FVX

Chemical Component Summary

NameFluvoxamine
Synonyms2-[({(1E)-5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene}amino)oxy]ethanamine
Systematic Name (OpenEye OEToolkits)2-[(E)-[5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene]amino]oxyethanamine
FormulaC15 H21 F3 N2 O2
Molecular Weight318.335
TypeNON-POLYMER

Chemical Descriptors

TypeProgram Version Descriptor
SMILESACDLabs12.01FC(F)(F)c1ccc(\C(=N\OCCN)CCCCOC)cc1
SMILESCACTVS3.370COCCCCC(=NOCCN)c1ccc(cc1)C(F)(F)F
SMILESOpenEye OEToolkits1.7.6COCCCCC(=NOCCN)c1ccc(cc1)C(F)(F)F
Canonical SMILESCACTVS3.370 COCCCC\C(=N/OCCN)c1ccc(cc1)C(F)(F)F
Canonical SMILESOpenEye OEToolkits1.7.6 COCCCC/C(=N\OCCN)/c1ccc(cc1)C(F)(F)F
InChIInChI1.03 InChI=1S/C15H21F3N2O2/c1-21-10-3-2-4-14(20-22-11-9-19)12-5-7-13(8-6-12)15(16,17)18/h5-8H,2-4,9-11,19H2,1H3/b20-14+
InChIKeyInChI1.03 CJOFXWAVKWHTFT-XSFVSMFZSA-N

Drug Info: DrugBank

DrugBank IDDB00176 
NameFluvoxamine
Groups
  • approved
  • investigational
DescriptionFluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database comprised of approximately 35,000 patients. It was launched in the US in December 1994 and in Japan in June 1999. As of the end of 1995, more than 10 million patients worldwide have been treated with fluvoxamine.
Synonyms
  • Fluvoxamine maleate
  • Fluvoxamina
  • Fluvoxamine
  • Fluvoxaminum
Brand Names
  • Fluvoxamine Tablets
  • PHL-fluvoxamine
  • Ava-fluvoxamine
  • Ratio-fluvoxamine
  • Fluvoxamine Maleate
IndicationIndicated predominantly for the management of depression and for Obsessive Compulsive Disorder (OCD) [FDA Label]. Has also been used in the management of bulimia nervosa [A250].
Categories
  • Amines
  • Anti-Anxiety Agents
  • Antidepressive Agents
  • Antidepressive Agents Indicated for Depression
  • Antidepressive Agents, Second-Generation
ATC-CodeN06AB08
CAS number54739-18-3

Drug Targets

NameTarget SequencePharmacological ActionActions
Sodium-dependent serotonin transporterMETTPLNSQKQLSACEDGEDCQENGVLQKVVPTPGDKVESGQISNGYSAV...unknowninhibitor
Potassium voltage-gated channel subfamily H member 2MPVRRGHVAPQNTFLDTIIRKFEGQSRKFIIANARVENCAVIYCNDGFCE...unknown
Cytochrome P450 2D6MGLEALVPLAVIVAIFLLLVDLMHRRQRWAARYPPGPLPLPGLGNLLHVD...unknownsubstrate,inhibitor
Cytochrome P450 1A2MALSQSVPFSATELLLASAIFCLVFWVLKGLRPRVPKGLKSPPEPWGWPL...unknownsubstrate,inhibitor
Cytochrome P450 1A1MLFPISMSATEFLLASVIFCLVFWVIRASRPQVPKGLKNPPGPWGWPLIG...unknowninhibitor
View More
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference
Pharos CHEMBL814
PubChem 5324346
ChEMBL CHEMBL814
ChEBI CHEBI:5138